Holen Sie sich die Stockscreener-App
2.24
3.23%
0.07
Handel nachbörslich:
2.22
-0.02
-0.89%
Schlusskurs vom Vortag:
$2.17
Offen:
$2.18
24-Stunden-Volumen:
404.99K
Relative Volume:
0.47
Marktkapitalisierung:
$245.60M
Einnahmen:
$45.44M
Nettoeinkommen (Verlust:
$-35.43M
KGV:
-6.5882
EPS:
-0.34
Netto-Cashflow:
$-25.39M
1W Leistung:
+0.45%
1M Leistung:
-0.88%
6M Leistung:
-46.02%
1J Leistung:
-39.78%
1-Tages-Spanne:
$2.145
$2.27
1-Wochen-Bereich:
$2.1335
$2.316
52-Wochen-Spanne:
$2.00
$5.20
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Vergleichen Sie MXCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
2.24 | 245.60M | 45.44M | -35.43M | -25.39M | -0.34 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing - Investing.com Australia
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies - The Manila Times
MaxCyte and Ori Biotech Forge Strategic Partnership to Enhance Cell Therapy Manufacturing Efficiency - Nasdaq
MaxCyte and Ori Biotech Join Forces to Transform CAR-T Cell Production Timeline and Efficiency - Stock Titan
MaxCyte and Ori Biotech Collaborate to Enhance Cell Therapy Manufacturing - TipRanks
Kalkine: NASDAQ Today Sees Movement in MaxCyte Amid Sector-Wide Shifts - Kalkine Media
Squarepoint Ops LLC Decreases Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
Two Sigma Advisers LP Purchases Shares of 17,800 MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Rating Increased to Hold at Wall Street Zen - Defense World
MaxCyte Announces Change in Voting Rights Structure - TipRanks
BlackRock Increases Stake in MaxCyte to 9.98% - TipRanks
Nuveen Asset Management LLC Cuts Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
ProShare Advisors LLC Has $143,000 Stake in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BNP Paribas Financial Markets Takes $56,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
BlackRock Increases Stake in MaxCyte - TipRanks
MaxCyte Expands Stock Capital Amidst Strategic Growth - TipRanks
Jane Street Group LLC Purchases 12,209 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte (NASDAQ:MXCT) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Deutsche Bank AG Buys 38,782 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
D. E. Shaw & Co. Inc. Buys 84,105 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte, Boosting Voting Rights - TipRanks
BlackRock Increases Stake in MaxCyte to 7.65% - TipRanks
Price T Rowe Associates Inc. MD Has $177,000 Position in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Shareholder Holdings - TipRanks
MaxCyte, Inc. (MXCT): A Bull Case Theory - MSN
MaxCyte Inc (MXCT): Be Patient, You Will Learn - Stocksregister
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2025 Earnings Call Transcript - Insider Monkey
MaxCyte’s Earnings Call: Navigating Challenges and Opportunities - TipRanks
William Blair Predicts MaxCyte’s Q2 Earnings (NASDAQ:MXCT) - Defense World
Hsbc Holdings PLC Purchases 16,554 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Files Form 10-Q for Q1 2025 - TipRanks
BTIG cuts MaxCyte stock price target to $5, maintains Buy rating - Investing.com
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know - MSN
Earnings call transcript: MaxCyte Q1 2025 beats revenue forecast, stock reacts - Investing.com
Wells Fargo & Company MN Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance - The Manila Times
MaxCyte Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Soleymannezhad Ali | Chief Commercial Officer |
Mar 18 '25 |
Sale |
3.18 |
1,211 |
3,850 |
59,439 |
| Sandoval David I. | GENERAL COUNSEL |
Mar 18 '25 |
Sale |
3.18 |
353 |
1,122 |
64,219 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Mar 18 '25 |
Sale |
3.18 |
6,939 |
22,061 |
111,811 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Jan 27 '25 |
Sale |
4.64 |
3,000 |
13,935 |
141,950 |
| Sandoval David I. | GENERAL COUNSEL |
Jan 13 '25 |
Sale |
4.54 |
4,466 |
20,272 |
41,447 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Option Exercise |
2.93 |
3,000 |
8,796 |
144,950 |
| Johnston John Joseph | Director |
Dec 26 '24 |
Sale |
4.01 |
3,000 |
12,021 |
141,950 |
0.54%
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):